 |
|
Delayed Allergic Reaction to Natalizumab Associated With Early Formation of Neutralizing Antibodies
Markus Krumbholz, MD;
Hannah Pellkofer, MD;
Ralf Gold, MD;
Lisa Ann Hoffmann, MD;
Reinhard Hohlfeld, MD;
Tania Kümpfel, MD
Arch Neurol. 2007;64(9):1331-1333.
Background Natalizumab is a new therapeutic option for relapsing-remitting multiple sclerosis. As with other antibody therapies, hypersensitivity reactions have been observed. In the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) trial, infusion-related hypersensitivity reactions developed in 4% of patients, usually within 2 hours after starting the infusion.
Objective To report a significant, delayed, serum sickness–like, type III systemic allergic reaction to natalizumab.
Design Case report describing clinical follow-up and the serial measurement of antinatalizumab antibodies.
Patient A 23-year-old man with relapsing-remitting multiple sclerosis developed a fever, arthralgias, urticarial exanthema, and a swollen lower lip during several days after his second infusion of natalizumab.
Results The patient developed a delayed, serum sickness–like, type III systemic allergic reaction to natalizumab. Five weeks after initiation of this therapy, he tested positive for antinatalizumab antibodies and exhibited persistent antibody titers 8 and 12 weeks later. His symptoms completely resolved with a short course of oral glucocorticosteroids.
Conclusion Clinicians and patients should be alert not only to immediate but also to significantly delayed substantial allergic reactions to natalizumab.
Author Affiliations: Institute for Clinical Neuroimmunology, Ludwig Maximilian University, Munich, Germany (Drs Krumbholz, Pellkofer, Hoffmann, Hohlfeld, and Kümpfel); and Department of Neurology, St Josef-Hospital, Ruhr University, Bochum, Germany (Dr Gold).
RELATED LETTERS
Type III Systemic Allergic Reaction to Natalizumab
Verena I. Leussink, Helmar C. Lehmann, Hans-Peter Hartung, Ralf Gold, and Bernd C. Kieseier
Arch Neurol. 2008;65(6):851-852.
EXTRACT
| FULL TEXT
Type III Systemic Allergic Reaction to Natalizumab—Reply
Markus Krumbholz, Hannah Pellkofer, Ralf Gold, Lisa Ann Hoffmann, Reinhard Hohlfeld, and Tania Kümpfel
Arch Neurol. 2008;65(6):852.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Review: Innovative monoclonal antibody therapies in multiple sclerosis
Linker and Kieseier
Therapeutic Advances in Neurological Disorders 2008;1:33-42.
ABSTRACT
Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer
Lin et al.
JCO 2008;26:2779-2780.
FULL TEXT
Type III Systemic Allergic Reaction to Natalizumab
Leussink et al.
Arch Neurol 2008;65:851-852.
FULL TEXT
Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy
Hellwig et al.
Arch Neurol 2008;65:656-658.
ABSTRACT
| FULL TEXT
|
